KelaHealth is a technology company.
KelaHealth has raised $13.0M across 2 funding rounds.
KelaHealth has raised $13.0M in total across 2 funding rounds.
KelaHealth is a San Francisco-based healthcare technology company that develops the Surgical Intelligence Platform, an AI-powered tool using machine learning to predict patient-specific surgical risks, recommend tailored interventions, and track outcomes.[1][2][3][4] It serves hospitals, surgeons, medtech companies, and payers by integrating seamlessly with electronic health records (EHRs) and partner applications to enhance perioperative care, reduce complications like acute kidney injury (AKI) and readmissions, and cut costs—demonstrated in clinical trials with a 21% AKI reduction, 24% readmission drop, and $1M savings in colorectal surgery.[3][4][5] The platform addresses inefficiencies in value-based care by shifting from subjective decisions to data-driven insights from over 6.5 million patient records, boosting throughput, efficiency, quality, and safety.[2][3]
KelaHealth spun out of Duke University in 2018, founded by surgeon-scientists including CEO Bora Chang, Dr. Erich Huang, and Dr. Zhifei Sun, who drew from their clinical experiences to create an objective, risk-based tool for surgical decisions.[3][4][5] The idea emerged from recognizing the need for data-driven personalization amid shifting healthcare paradigms from volume- to value-based models, combining clinician expertise with machine learning on millions of patient records.[1][3] Early traction included NSF SBIR Phase II funding for its adaptive ML platform, clinical validations at Duke showing 41% surgical site infection reductions and cost savings, and partnerships like Advocate Aurora Research Institute backed by investors such as Intuitive Surgical and Sante Ventures.[4][7]
KelaHealth rides the AI-in-healthcare wave, specifically perioperative analytics amid the value-based care shift, where hospitals face pressure to cut costs (e.g., readmissions) while improving outcomes—exacerbated by post-pandemic throughput demands.[1][2][5] Timing aligns with EHR maturity and medtech convergence, enabling scalable integrations; market forces like rising surgical volumes and investor demands for clinical proof favor evidence-backed players like KelaHealth, which influences the ecosystem by validating AI via trials and partnerships, setting standards for "surgical intelligence" and accelerating adoption.[3][4][5]
KelaHealth's commercial momentum—fueled by Duke validations, marquee partnerships, and NSF backing—positions it for expansion into more surgical specialties and global markets, potentially powering broader medtech ecosystems.[3][4][7] Trends like multimodal AI (clinical + device data) and regulatory emphasis on real-world evidence will amplify its edge, evolving its role from risk predictor to full surgical orchestrator amid tightening healthcare budgets. As a clinician-founded innovator, it exemplifies how AI can humanize high-stakes surgery, delivering the personalized care that defines next-gen healthtech.[1][3]
KelaHealth has raised $13.0M in total across 2 funding rounds.
KelaHealth's investors include Intuitive Ventures, Santé Ventures.
KelaHealth has raised $13.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $3.0M Seed | Intuitive Ventures, Santé Ventures | |
| Oct 1, 2020 | $10.0M Series A | Intuitive Ventures, Santé Ventures |